Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (61-70 of 280) with videos related to

Pageof 28
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|February 6, 2014
Pathology of systemic lupus erythematosus: the challenges aheadPedro Correia Azevedo, Grainne Murphy, David A Isenberg
Clinical and Experimental Rheumatology|August 6, 2016
Why do patients with myositis die? A retrospective analysis of a single-centre cohortMarta Amaral Silva, Estefania Cogollo, David A Isenberg
Expert Review of Clinical Pharmacology|December 29, 2015
Current pharmacological treatment of idiopathic inflammatory myopathiesSerena Fasano, Sara Custódio Alves, David A Isenberg
Pharmacogenomics and Personalized Medicine|February 27, 2020
Towards Precision Medicine in Systemic Lupus ErythematosusElliott Lever, Marta R Alves, David A Isenberg
Rheumatology (Oxford, England)|March 19, 2011
Assessment of a lupus nephritis cohort over a 30-year periodSara C Croca, Teresa Rodrigues, David A Isenberg
Annals of the Rheumatic Diseases|July 14, 2007
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?Sean G O'Neill, David A Isenberg, Anisur Rahman
RMD Open|October 29, 2015
Belimumab in systemic lupus erythematosusAndreia Vilas-Boas, Sandra A Morais, David A Isenberg
Journal of Autoimmunity|July 28, 2016
The diagnosis and management of the haematologic manifestations of lupusAlba Velo-García, Sara Guerreiro Castro, David A Isenberg
Lupus|February 20, 2025
Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapyPedro Gaspar, Prabal Mittal, Hannah Cohen, et al.
Lupus Science & Medicine|August 25, 2015
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II studyMurray B Urowitz, David A Isenberg, Daniel J Wallace
Pageof 28

Showing results (61-70 of 280) with videos related to

Sort By:
Pageof 28
Methods in Molecular Biology (Clifton, N.J.)|February 6, 2014
Pathology of systemic lupus erythematosus: the challenges aheadPedro Correia Azevedo, Grainne Murphy, David A Isenberg
Clinical and Experimental Rheumatology|August 6, 2016
Why do patients with myositis die? A retrospective analysis of a single-centre cohortMarta Amaral Silva, Estefania Cogollo, David A Isenberg
Expert Review of Clinical Pharmacology|December 29, 2015
Current pharmacological treatment of idiopathic inflammatory myopathiesSerena Fasano, Sara Custódio Alves, David A Isenberg
Pharmacogenomics and Personalized Medicine|February 27, 2020
Towards Precision Medicine in Systemic Lupus ErythematosusElliott Lever, Marta R Alves, David A Isenberg
Rheumatology (Oxford, England)|March 19, 2011
Assessment of a lupus nephritis cohort over a 30-year periodSara C Croca, Teresa Rodrigues, David A Isenberg
Annals of the Rheumatic Diseases|July 14, 2007
Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?Sean G O'Neill, David A Isenberg, Anisur Rahman
RMD Open|October 29, 2015
Belimumab in systemic lupus erythematosusAndreia Vilas-Boas, Sandra A Morais, David A Isenberg
Journal of Autoimmunity|July 28, 2016
The diagnosis and management of the haematologic manifestations of lupusAlba Velo-García, Sara Guerreiro Castro, David A Isenberg
Lupus|February 20, 2025
Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapyPedro Gaspar, Prabal Mittal, Hannah Cohen, et al.
Lupus Science & Medicine|August 25, 2015
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II studyMurray B Urowitz, David A Isenberg, Daniel J Wallace
Pageof 28